Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

S. Singhal*, R. Powles, B. Sirohi, J. Treleaven, S. Kulkarni, J. Mehta

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Fingerprint

Dive into the research topics of 'Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology